Research presented at the 2021 American Society of Health-System Pharmacists (ASHP) Specialty Pharmacy Conference suggests overall medical expenses for oncology patients were significantly improved by using an integrated health-system specialty pharmacy (HSSP) care model.
The objective of the study was to design and implement a useful tool to record ambulatory metrics that is reportable and can be easily integrated into the clinical workflow.
The American Society of Health-System Pharmacists’ (ASHP) first annual survey of health-system specialty pharmacies (HSSPs) offered insights into the concerns of specialty pharmacists and provided an opportunity for professionals in the field to outline a potential future for specialty pharmacy.
The pipeline for biosimilar products in the United States includes at least 26 candidates in phase 3 trials for 13 reference therapies.
White continued to discuss how being self-aware, using the right language, modeling behaviors that support belonging, and fostering an environment with psychological safety is the goal as a a health care provider.
In one program, hospital pharmacists received alerts whenever an antiretroviral was prescribed in the emergency department, enabling prompt action.
Specialty pharmacists have the expertise and respect necessary to change the health care system while listening to patients’ needs and guiding them through difficult experiences.
Pharmacy Times spoke with Bhavesh Shah, associate chief pharmacy officer for hematology/oncology, about his session titled Stand Strong Against Platelet Destruction With Tavalisse®: A Patient’s ITP Treatment Journey, which he presented at the 2021 ATOPP Summit.
Mary Reed, DrPH, research scientist at Kaiser Permanente, discussed the challenges encountered by health systems and patients during the shift to online care.
Pharmacy Times spoke with Bhavesh Shah, associate chief pharmacy officer for hematology/oncology, about his session titled Stand Strong Against Platelet Destruction With Tavalisse®: A Patient’s ITP Treatment Journey, which he presented at the 2021 ATOPP Summit.
Similar effects were seen both with and without an SGLT2 inhibitor, according to investigators.
Pharmacy Times spoke with Bhavesh Shah, associate chief pharmacy officer for hematology/oncology, about his session titled Stand Strong Against Platelet Destruction With Tavalisse®: A Patient’s ITP Treatment Journey, which he presented at the 2021 ATOPP Summit.
Mary Reed, DrPH, research scientist at Kaiser Permanente, discussed the changes made to health care practices in light of the COVID-19 pandemic that she would like to see remain in place in the future.
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the implications of the DARE-19 trial results assessing dapagliflozin as a treatment for patients with type 2 diabetes hospitalized with COVID-19.
Mary Reed, DrPH, research scientist at Kaiser Permanente, discussed how COVID-19 forced health systems to shift primarily to telehealth, and the impact this had on patients with diabetes.
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed what some of the adverse events experienced by patients were, and how patients were able to handle them.
Patients with diabetes treated with liraglutide also saw more weight loss compared with patients in the other arms of the study.
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the research assessing dapagliflozin advanced from cardiorenal effects to prevention and organ protection.
The drug is approved for patients after 4 or more failed lines of therapy, although many patients in clinical trials had received 7 or more prior lines of therapy.
Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses how the results from the phase 3 trial evaluating an investigational 2 mg dose of semaglutide could change treatment options for patients with type 2 diabetes.
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the results of the DARE-19 trial are important to the field, especially during the COVID-19 pandemic.
Drugs to treat type 2 diabetes using SGLT2 inhibitors are relatively new, with FDA approvals only within the last decade.
Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the benefit of the investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes.
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed how the phase 3 DARE-19 trial was conducted to assess dapagliflozin in patients with type 2 diabetes hospitalized with COVID-19.
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the safety profile of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19 during the DARE-19 trial.
Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the adverse events experienced by patients during the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes.
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the efficacy of dapagliflozin in the DARE-19 trial assessing its efficacy and safety in patients with type 2 diabetes hospitalized with COVID-19.
Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses how the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes was conducted.
Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the findings around the efficacy and safety of the 2 mg dose of semaglutide for the treatment of type 2 diabetes.
The results from the first phase 3 SURPASS trials showed promising results with tirzepatide in patients with type 2 diabetes.
